A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
The present clinical trial is aiming to evaluate efficacy of ARQ 197 in patients with
hepatocellular carcinoma (HCC), who were resistant or intolerable to one systemic
chemotherapy regimen including sorafenib.